Media & Resources

New York, November 30, 2010— The International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of Jane Waterman to its management team as Executive Director, Europe. Waterman, who will be based in IAVI’s Amsterdam office, will direct IAVI’s operations in Europe. Leading a team of 13 staff members, she will oversee activities including…

The International AIDS Vaccine Initiative (IAVI) welcomes the news that in a Phase III clinical pre-exposure prophylaxis (PrEP) trial, daily dosing with a combination of two antiretroviral medications reduced the risk of HIV acquisition in men who have sex with men and are at high risk of HIV infection. In the trial–known as the Pre-Exposure…

NineSigma and IAVI Partner to Find Novel Solutions to Support the Development of an AIDS Vaccine The International AIDS Vaccine Initiative (IAVI) will utilize NineSigma’s proven Open Innovation approach to find breakthrough protein-stabilizing solutions that can be used to create an effective AIDS vaccine. CLEVELAND, Ohio – October 26, 2010 – NineSigma, the leading provider…

New York, October 22, 2010 —The International AIDS Vaccine Initiative (IAVI) today announced the start of a Phase I clinical trial to evaluate the safety and immunogenicity of two preventive AIDS vaccine candidates. The trial, called B003/IPCAVD-004, is the first to test these vaccine candidates in a prime-boost combination, a regimen in which vaccines are given…

NEW YORK, September 27, 2010— A team of investigators headed by International AIDS Vaccine Initiative (IAVI) Investigator Pascal Poignard has been awarded a major grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health (NIH) to investigate the biological mechanisms underlying the generation of broadly neutralizing antibodies by…

New York, August 10, 2010 — The International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of Michael Caulfield as Executive Director of the IAVI AIDS Vaccine Design and Development Laboratory (DDL). Dr. Caulfield comes to IAVI from Merck, where he worked for 16 years, joining as a research fellow and rising to become…

New York, July 22, 2010—While celebrating news that a vaginal gel had for the first time demonstrated effectiveness at protecting women against HIV protection, health experts at the biannual International AIDS Conference this week in Vienna also trumpeted a new era in the effort to develop the long-sought AIDS vaccine. “There is a renaissance going…

VIENNA, 21 July, 2010 – Following significant advances in vaccine and microbicide research, importantly including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention research may limit researchers’ ability to quickly move promising approaches forward.…